Search research articles
Contact Us
Filters
Showing results (51-60 of 501) with videos related to
Page
of 51
Sort By:
The Medical Journal of Australia
|
June 4, 2023
Avoiding severe drug hypersensitivity reactions: a case for HLA genotyping for at-risk patients
Jana Stojanova, Richard O Day, Graeme Suthers
The Medical Journal of Australia
|
April 5, 2012
Time for the Pharmaceutical Benefits Advisory Committee to set its own agenda
Wendy L Lipworth, Ian Kerridge, Richard O Day
Nature
|
January 31, 1975
Nucleic acid-mutagen interactions: crystal structure of adenylyl-3',5'-uridine plus 9-aminoacridine
N C Seeman, R O Day, A Rich
Emergency Medicine Australasia : EMA
|
June 15, 2007
Utility of urine drug screening: a clinical audit
Bridin P Murnion, Ron Granot, Richard O Day
British Journal of Clinical Pharmacology
|
May 13, 1998
Indicators for drug and therapeutics committees
L M Weekes, C Brooks, R O Day
International Journal of Medical Informatics
|
April 28, 2015
Identifying effective computerized strategies to prevent drug-drug interactions in hospital: A user-centered approach
Olivia Missiakos, Melissa T Baysari, Richard O Day
The Journal of Prosthetic Dentistry
|
May 1, 1980
Clinical considerations for root-submergence procedures
P Delivanis, O Day, C Esposito, et al.
Nature Reviews. Rheumatology
|
September 30, 2015
Allopurinol hypersensitivity: investigating the cause and minimizing the risk
Lisa K Stamp, Richard O Day, James Yun
Emergency Medicine Australasia : EMA
|
June 18, 2019
Role and impact of brain computed tomography in the management of drug overdoses and guideline recommendations
Emma My Tay, Paul Preisz, Richard O Day
Free Radical Research Communications
|
January 1, 1993
Identification of products from oxidation of uric acid induced by hydroxyl radicals
M Hicks, L S Wong, R O Day
Page
of 51
Search research articles
Search
Showing results (51-60 of 501) with videos related to
Sort By:
Page
of 51
The Medical Journal of Australia
|
June 4, 2023
Avoiding severe drug hypersensitivity reactions: a case for HLA genotyping for at-risk patients
Jana Stojanova, Richard O Day, Graeme Suthers
The Medical Journal of Australia
|
April 5, 2012
Time for the Pharmaceutical Benefits Advisory Committee to set its own agenda
Wendy L Lipworth, Ian Kerridge, Richard O Day
Nature
|
January 31, 1975
Nucleic acid-mutagen interactions: crystal structure of adenylyl-3',5'-uridine plus 9-aminoacridine
N C Seeman, R O Day, A Rich
Emergency Medicine Australasia : EMA
|
June 15, 2007
Utility of urine drug screening: a clinical audit
Bridin P Murnion, Ron Granot, Richard O Day
British Journal of Clinical Pharmacology
|
May 13, 1998
Indicators for drug and therapeutics committees
L M Weekes, C Brooks, R O Day
International Journal of Medical Informatics
|
April 28, 2015
Identifying effective computerized strategies to prevent drug-drug interactions in hospital: A user-centered approach
Olivia Missiakos, Melissa T Baysari, Richard O Day
The Journal of Prosthetic Dentistry
|
May 1, 1980
Clinical considerations for root-submergence procedures
P Delivanis, O Day, C Esposito, et al.
Nature Reviews. Rheumatology
|
September 30, 2015
Allopurinol hypersensitivity: investigating the cause and minimizing the risk
Lisa K Stamp, Richard O Day, James Yun
Emergency Medicine Australasia : EMA
|
June 18, 2019
Role and impact of brain computed tomography in the management of drug overdoses and guideline recommendations
Emma My Tay, Paul Preisz, Richard O Day
Free Radical Research Communications
|
January 1, 1993
Identification of products from oxidation of uric acid induced by hydroxyl radicals
M Hicks, L S Wong, R O Day
Page
of 51